Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.

BMC gastroenterology - 14 Sept 2015

Masola Valentina, Carraro Amedeo, Zaza Gianluigi, Bellin Gloria, Montin Umberto, Violi Paola, Lupo Antonio, Tedeschi Umberto

Abstract excerpt

BACKGROUND: Everolimus (EVE), a mammalian target of rapamycin inhibitor, has been proposed as liver transplant immunosuppressive drug, gaining wide interest also for the treatment of cancer. Although an appropriate tolerance, it may induce several adverse effects, such as fibro-interstitial pneumonitis due to the acquisition of activated myofibroblasts. The exact molecular mechanism associated with epithelial to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epithelial-Mesenchymal Transition
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibronectins

Share to Hep G2 Cells

Share to Hepatic Stellate Cells

Share to Immunosuppressive Agents

Share to Rats, Wistar

Share to Vimentin

Source

Open in PubMed Open full text

Identifiers

PMID: 26369804
DOI: 10.1186/s12876-015-0347-6
PMCID: PMC4570634

Genes

VIM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro.PMID 26369804Read ↗

High dose everolimus promotes a pro-inflammatory phenotype and facilitates the epithelial to mesenchymal transition of primary bronchial epithelial cells isolated from cystic fibrosis patients.Semantic proximity Read ↗

Is the Epithelial-to-Mesenchymal Transition Clinically Relevant for the Cancer Patient?Semantic proximity Read ↗

Exosomes of mesenchymal stem cells reduce cholesterol-induced hepatic fibrogenesis by inhibiting TGF-β/Smad3 signaling pathway in LX2 cellsSemantic proximity Read ↗

The transforming growth factor-beta (TGF-β) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells.Semantic proximity Read ↗

[Epithelial to mesenchymal phenotype transition in the liver of rats with bile duct ligation].Semantic proximity Read ↗

Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.Semantic proximity Read ↗

Epithelial to mesenchymal transition is associated with rapamycin resistance.Semantic proximity Read ↗

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.Semantic proximity Read ↗

Epithelial vs myofibroblast differentiation in immortal rat lung cell lines--modulating effects of bleomycin.Semantic proximity Read ↗

Microparticles derived from human erythropoietin mRNA-transfected mesenchymal stem cells inhibit epithelial-to-mesenchymal transition and ameliorate renal interstitial fibrosisSemantic proximity Read ↗

[Experimental study of epithelial-mesenchymal transition induced by HBx protein in liver cancer cell].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.